GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » 12-1 Month Momentum %

Easton Pharmaceuticals (Easton Pharmaceuticals) 12-1 Month Momentum % : N/A% (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-25), Easton Pharmaceuticals's 12-1 Month Momentum % is N/A%.

The industry rank for Easton Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

EAPH's 12-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -9.09
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of Easton Pharmaceuticals's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Easton Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Easton Pharmaceuticals's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easton Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Easton Pharmaceuticals's 12-1 Month Momentum % falls into.



Easton Pharmaceuticals  (OTCPK:EAPH) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Easton Pharmaceuticals  (OTCPK:EAPH) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Easton Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Easton Pharmaceuticals (Easton Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.

Easton Pharmaceuticals (Easton Pharmaceuticals) Headlines

From GuruFocus

Easton Pharmaceuticals Announces BAYER Agreement Update

By Marketwired Marketwired 04-16-2018